Bispecific antibody-drug conjugate targeting EGFR and HER3; after internalization, releases a topoisomerase I inhibitor payload (brengitecan) to induce DNA damage and tumor cell death.
Bispecific ADC that binds EGFR and HER3 on tumor cells, is internalized, and releases the topoisomerase I inhibitor payload brengitecan to induce DNA damage and tumor cell death.
NO
INDIRECT
The ADC binds EGFR/HER3 on tumor cells, is internalized, and releases the topoisomerase I inhibitor brengitecan, which inhibits Topoisomerase I to cause DNA damage and cell death; Topoisomerase I itself is not the binding/targeting antigen.
A CD20×CD3 T-cell–engaging bispecific humanized monoclonal antibody that binds CD20 on B cells and CD3 on T cells, redirecting and activating T cells to kill CD20+ lymphoma cells via perforin/granzyme-mediated cytotoxicity.
CD20×CD3 bispecific humanized monoclonal antibody that binds CD20 on B cells and CD3 on T cells, crosslinking them to redirect and activate T cells to kill CD20+ B‑cell malignancies via perforin/granzyme-mediated cytotoxicity.
YES
DIRECT
Glofitamab crosslinks CD20 on target cells with CD3 on T cells, activating T cells to kill CD20+ cells via perforin/granzyme-mediated cytolysis.
A CD20×CD3 T-cell–engaging bispecific humanized monoclonal antibody that binds CD20 on B cells and CD3 on T cells, redirecting and activating T cells to kill CD20+ lymphoma cells via perforin/granzyme-mediated cytotoxicity.
CD20×CD3 bispecific humanized monoclonal antibody that binds CD20 on B cells and CD3 on T cells, crosslinking them to redirect and activate T cells to kill CD20+ B‑cell malignancies via perforin/granzyme-mediated cytotoxicity.
NO
INDIRECT
Glofitamab binds CD3ε on T cells to recruit/activate them and crosslink to CD20+ B cells; the activated T cells kill the CD20+ targets via perforin/granzyme, not the CD3+ cells.
A humanized, glycoengineered type II anti-CD20 monoclonal antibody that induces direct B‑cell death and enhances antibody-dependent cellular cytotoxicity and phagocytosis.
Humanized, glycoengineered type II anti‑CD20 IgG1 that binds CD20 on B cells and drives B‑cell depletion via direct caspase‑independent cell death and enhanced Fc‑mediated effector functions (ADCC and phagocytosis) through increased FcγRIIIa binding.
YES
DIRECT
Obinutuzumab binds CD20 on B cells, triggering direct caspase-independent cell death and engaging Fc-gamma RIIIa on effector cells to mediate ADCC and phagocytosis, leading to target-cell killing.
Chimeric anti-CD20 monoclonal antibody that depletes CD20+ B cells via complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and apoptosis.
Anti-CD20 chimeric monoclonal antibody that binds CD20 on pre-B and mature B cells and depletes them via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and induction of apoptosis.
YES
DIRECT
Rituximab binds CD20 on B cells and depletes them via complement-dependent cytotoxicity (CDC), Fc-mediated antibody-dependent cellular cytotoxicity (ADCC) by NK cells/macrophages, and direct induction of apoptosis.